Company / Cash & Equivalents
CHAMPIONS ONCOLOGY, INC. Cash & Equivalents History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$3.2M
FY2019
5-year range
-
FY2016-FY2019
Trend
+278.2%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +278% YoY in FY2019, a notable deviation from the 3-year average annual change of +46%.
Based on SEC 10-K filings.
$3M in FY2019 with a 3-year CAGR of -29.8%.
Improved from $3M to $3M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -29.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -29.8%, indicating a declining trend.
- In FY2019, cash & equivalents increased 278.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $3.2M | +278.2% |
| FY2018 | $856.0K | -66.9% |
| FY2017 | $2.6M | -72.4% |
| FY2016 | $9.4M | +58.8% |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026